Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

Hours after Adaptimmune Therapeutics PLC saw its stock soar 200% following a positive presentation at the J.P. Morgan Healthcare Conference in San Francisco, the UK firm has inked a major deal with Astellas Pharma Inc. to develop up to three T-cell therapies.

The Japanese drugmaker's subsidiary Universal Cells Inc. will work with Adaptimmune to develop stem-cell derived allogeneic ‘off-the-shelf’ T-cell therapies for cancer, having signed a co-development and co-marketing agreement that could be worth up to $897